Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.
2.

An exploration of ontology-based EMR data abstraction for diabetic kidney disease prediction.

Song X, Waitman LR, Hu Y, Yu ASL, Robbins D, Liu M.

AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:704-713. eCollection 2019.

3.

Tungsten filled 3D printed field shaping devices for electron beam radiation therapy.

Skinner L, Fahimian BP, Yu AS.

PLoS One. 2019 Jun 19;14(6):e0217757. doi: 10.1371/journal.pone.0217757. eCollection 2019.

4.

Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Hayek SS, Landsittel DP, Wei C, Zeier M, Yu ASL, Torres VE, Roth S, Pao CS, Reiser J.

J Am Soc Nephrol. 2019 Jul;30(7):1305-1313. doi: 10.1681/ASN.2018121227. Epub 2019 Jun 6.

PMID:
31171572
5.

Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.

Bae KT, Zhou W, Shen C, Landsittel DP, Wu Z, Tao C, Chapman AB, Torres VE, Yu ASL, Mrug M, Bennett WM, Harris PC; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):823-833. doi: 10.2215/CJN.10360818. Epub 2019 May 14.

PMID:
31088850
6.

Novel Risk Loci Identified in a Genome-Wide Association Study of Urolithiasis in a Japanese Population.

Tanikawa C, Kamatani Y, Terao C, Usami M, Takahashi A, Momozawa Y, Suzuki K, Ogishima S, Shimizu A, Satoh M, Matsuo K, Mikami H, Naito M, Wakai K, Yamaji T, Sawada N, Iwasaki M, Tsugane S, Kohri K, Yu ASL, Yasui T, Murakami Y, Kubo M, Matsuda K.

J Am Soc Nephrol. 2019 May;30(5):855-864. doi: 10.1681/ASN.2018090942. Epub 2019 Apr 11.

PMID:
30975718
7.

Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, Chapman AB, Bae KT, Mrug M, Harris PC, Rahbari-Oskoui FF, Shi T, Bennett WM; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2019 May;95(5):1253-1261. doi: 10.1016/j.kint.2018.12.023. Epub 2019 Mar 4.

PMID:
30922668
8.

Paracellular calcium transport in the proximal tubule and the formation of kidney stones.

Curry JN, Yu ASL.

Am J Physiol Renal Physiol. 2019 May 1;316(5):F966-F969. doi: 10.1152/ajprenal.00519.2018. Epub 2019 Mar 6.

PMID:
30838875
9.

Robust clinical marker identification for diabetic kidney disease with ensemble feature selection.

Song X, Waitman LR, Hu Y, Yu ASL, Robins D, Liu M.

J Am Med Inform Assoc. 2019 Mar 1;26(3):242-253. doi: 10.1093/jamia/ocy165.

PMID:
30602020
10.

Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.

McKenzie KA, El Ters M, Torres VE, Harris PC, Chapman AB, Mrug M, Rahbari-Oskoui FF, Bae KT, Landsittel DP, Bennett WM, Yu ASL, Mahnken JD.

BMC Nephrol. 2018 Dec 27;19(1):378. doi: 10.1186/s12882-018-1182-0.

11.

Feature Ranking in Predictive Models for Hospital-Acquired Acute Kidney Injury.

Wu L, Hu Y, Liu X, Zhang X, Chen W, Yu ASL, Kellum JA, Waitman LR, Liu M.

Sci Rep. 2018 Nov 23;8(1):17298. doi: 10.1038/s41598-018-35487-0.

12.

Regulation of Orai/STIM Channels by pH.

Yu AS, Yue Z, Feng J, Yue L.

In: Kozak JA, Putney JW Jr., editors. Calcium Entry Channels in Non-Excitable Cells. Boca Raton (FL): CRC Press/Taylor & Francis; 2018. Chapter 9.

13.

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE.

J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18. Review.

PMID:
30228150
14.

Magnesium Handling in the Kidney.

Curry JN, Yu ASL.

Adv Chronic Kidney Dis. 2018 May;25(3):236-243. doi: 10.1053/j.ackd.2018.01.003. Review.

PMID:
29793662
15.

A novel-integrated quality assurance phantom for radiographic and nonradiographic radiotherapy localization and positioning systems.

Yu AS, Fowler TL, Dubrowski P.

Med Phys. 2018 Jul;45(7):2857-2863. doi: 10.1002/mp.12950. Epub 2018 May 23.

PMID:
29730884
16.

Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC.

Am J Hum Genet. 2018 May 3;102(5):832-844. doi: 10.1016/j.ajhg.2018.03.013. Epub 2018 Apr 26.

17.

Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?

Mustafa RA, Yu ASL.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1107-1109. doi: 10.2215/CJN.00190118. Epub 2018 Apr 13. No abstract available.

18.

Chest wall dose reduction using noncoplanar volumetric modulated arc radiation therapy for lung stereotactic ablative radiation therapy.

Yu AS, Maxim PG, Loo BW Jr, Gensheimer MF.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):e199-e207. doi: 10.1016/j.prro.2017.12.005. Epub 2017 Dec 19.

PMID:
29452868
19.

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Cornec-Le Gall E, Chebib FT, Madsen CD, Senum SR, Heyer CM, Lanpher BC, Patterson MC, Albright RC, Yu AS, Torres VE; HALT Progression of Polycystic Kidney Disease Group Investigators, Harris PC.

Am J Kidney Dis. 2018 Aug;72(2):302-308. doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1.

20.

Intrafractional Tracking Accuracy of a Transperineal Ultrasound Image Guidance System for Prostate Radiotherapy.

Yu AS, Najafi M, Hristov DH, Phillips T.

Technol Cancer Res Treat. 2017 Dec;16(6):1067-1078. doi: 10.1177/1533034617728643. Epub 2017 Sep 21.

21.

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.

22.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

23.

Sexual Dimorphic Pattern of Renal Transporters and Electrolyte Homeostasis.

Veiras LC, Girardi ACC, Curry J, Pei L, Ralph DL, Tran A, Castelo-Branco RC, Pastor-Soler N, Arranz CT, Yu ASL, McDonough AA.

J Am Soc Nephrol. 2017 Dec;28(12):3504-3517. doi: 10.1681/ASN.2017030295. Epub 2017 Aug 3.

24.

Paracellular transport and energy utilization in the renal tubule.

Yu ASL.

Curr Opin Nephrol Hypertens. 2017 Sep;26(5):398-404. doi: 10.1097/MNH.0000000000000348. Review.

PMID:
28617689
25.

Paracellular transport as a strategy for energy conservation by multicellular organisms?

Yu ASL.

Tissue Barriers. 2017 Apr 3;5(2):e1301852. doi: 10.1080/21688370.2017.1301852. Epub 2017 Mar 3.

26.

Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.

Shen C, Landsittel D, Irazabal MV, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE; CRISP Investigators.

Am J Kidney Dis. 2017 Mar;69(3):482-484. doi: 10.1053/j.ajkd.2016.10.021. Epub 2016 Dec 24. No abstract available.

27.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

28.

Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.

Sinha Ray A, Haikal A, Hammoud KA, Yu AS.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2132-2140. Epub 2016 Nov 28. Review.

29.

Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease.

Kim Y, Bae SK, Cheng T, Tao C, Ge Y, Chapman AB, Torres VE, Yu AS, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT.

Phys Med Biol. 2016 Nov 21;61(22):7864-7880. Epub 2016 Oct 25.

30.

Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.

Ghezzi C, Yu AS, Hirayama BA, Kepe V, Liu J, Scafoglio C, Powell DR, Huang SC, Satyamurthy N, Barrio JR, Wright EM.

J Am Soc Nephrol. 2017 Mar;28(3):802-810. doi: 10.1681/ASN.2016050510. Epub 2016 Sep 12.

31.

Current Challenges in the Evaluation and Management of Hyponatremia.

McGreal K, Budhiraja P, Jain N, Yu AS.

Kidney Dis (Basel). 2016 Jun;2(2):56-63. doi: 10.1159/000446267. Epub 2016 May 14. Review.

32.

An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery.

Zeng H, Guo M, Zhou T, Tan L, Chong CN, Zhang T, Dong X, Xiang JZ, Yu AS, Yue L, Qi Q, Evans T, Graumann J, Chen S.

Cell Stem Cell. 2016 Sep 1;19(3):326-40. doi: 10.1016/j.stem.2016.07.002. Epub 2016 Aug 11.

33.

Clinical Trials in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, El-Ters M, Winklhofer FT.

In: Li X, editor. Polycystic Kidney Disease [Internet]. Brisbane (AU): Codon Publications; 2015 Nov. Chapter 6.

34.

Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE; HALT Investigators.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1857-1865. doi: 10.1093/ndt/gfw294.

35.

Claudin-2-mediated cation and water transport share a common pore.

Rosenthal R, Günzel D, Krug SM, Schulzke JD, Fromm M, Yu AS.

Acta Physiol (Oxf). 2017 Feb;219(2):521-536. doi: 10.1111/apha.12742. Epub 2016 Jul 20.

36.

Paracellular epithelial sodium transport maximizes energy efficiency in the kidney.

Pei L, Solis G, Nguyen MT, Kamat N, Magenheimer L, Zhuo M, Li J, Curry J, McDonough AA, Fields TA, Welch WJ, Yu AS.

J Clin Invest. 2016 Jul 1;126(7):2509-18. doi: 10.1172/JCI83942. Epub 2016 May 23.

37.

A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.

Kakade VR, Tao S, Rajagopal M, Zhou X, Li X, Yu AS, Calvet JP, Pandey P, Rao R.

J Mol Cell Biol. 2016 Dec;8(6):464-476. Epub 2016 May 4.

38.

Engineered BDNF producing cells as a potential treatment for neurologic disease.

Deng P, Anderson JD, Yu AS, Annett G, Fink KD, Nolta JA.

Expert Opin Biol Ther. 2016 Aug;16(8):1025-33. doi: 10.1080/14712598.2016.1183641. Epub 2016 May 21. Review.

39.

Investigation and control of a Plasmodium falciparum malaria outbreak in Shan Special Region II of Myanmar along the China-Myanmar Border from June to December 2014.

Liu H, Xu JW, Yang HL, Li M, Sun CD, Yin YJ, Zheng ZL, Zhang GY, Yu AS, Yang YH, Li CH, Ai S.

Infect Dis Poverty. 2016 Apr 25;5:32. doi: 10.1186/s40249-016-0127-8.

40.

Cognitive Function and White Matter Changes Associated with Renal Transplantation.

Gupta A, Lepping RJ, Yu AS, Perea RD, Honea RA, Johnson DK, Brooks WM, Burns JM.

Am J Nephrol. 2016;43(1):50-7. doi: 10.1159/000444334. Epub 2016 Feb 20.

41.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

42.

Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease.

Kim Y, Ge Y, Tao C, Zhu J, Chapman AB, Torres VE, Yu AS, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2016 Apr 7;11(4):576-84. doi: 10.2215/CJN.08300815. Epub 2016 Jan 21.

43.

Water and ion permeability of a claudin model: A computational study.

Laghaei R, Yu AS, Coalson RD.

Proteins. 2016 Mar;84(3):305-15. doi: 10.1002/prot.24969. Epub 2016 Feb 1.

44.

Identification of key amino acid residues responsible for internal and external pH sensitivity of Orai1/STIM1 channels.

Tsujikawa H, Yu AS, Xie J, Yue Z, Yang W, He Y, Yue L.

Sci Rep. 2015 Nov 18;5:16747. doi: 10.1038/srep16747.

45.

Claudin-2-dependent paracellular channels are dynamically gated.

Weber CR, Liang GH, Wang Y, Das S, Shen L, Yu AS, Nelson DJ, Turner JR.

Elife. 2015 Nov 14;4:e09906. doi: 10.7554/eLife.09906.

46.

Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.

Yu AS, Zhao L.

Tumour Biol. 2016 Apr;37(4):4857-64. doi: 10.1007/s13277-015-4344-8. Epub 2015 Nov 2.

PMID:
26526575
47.

How specific is CRISPR/Cas9 really?

O'Geen H, Yu AS, Segal DJ.

Curr Opin Chem Biol. 2015 Dec;29:72-8. doi: 10.1016/j.cbpa.2015.10.001. Epub 2015 Oct 24. Review.

48.

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE.

Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15.

49.

Anatomic optimization of lung tumor stereotactic ablative radiation therapy.

Yu AS, von Eyben R, Yamamoto T, Diehn M, Shultz DB, Loo BW Jr, Maxim PG.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e607-13. doi: 10.1016/j.prro.2015.05.008. Epub 2015 Jul 28.

PMID:
26231596
50.

Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.

Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS.

J Am Soc Nephrol. 2016 Jan;27(1):305-13. doi: 10.1681/ASN.2014111063. Epub 2015 Jul 30.

Supplemental Content

Support Center